Physician profile
Michael Piesman
NPI 1750402046
$8,126.89
in general payments reported to CMS, 2019-2025
35 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $221 · 2021: $707 · 2022: $1,363 · 2023: $1,763 · 2024: $1,740 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,033.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,554.56 | 2019-2025 | |
| Janssen Biotech, INC. | $1,078.67 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $886.83 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $628.81 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $337.95 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $279.19 | 2019-2025 | |
| Pfizer INC. | $269.00 | 2019-2025 | |
| Genzyme Corporation | $235.28 | 2022-2025 | |
| Boston Scientific Corporation | $181.06 | 2024 | Exalt Model D, Wallflex Duodenal, Cre Pro |
| Qol Medical, LLC | $165.52 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $142.51 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $141.49 | 2021-2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $123.15 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $107.14 | 2019-2022 | |
| Madrigal Pharmaceuticals | $103.88 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $93.19 | 2020-2024 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $90.13 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $87.67 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $73.79 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $70.32 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $61.55 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $55.98 | 2021 | |
| Phathom Pharmaceuticals, INC. | $52.37 | 2024-2025 | Voquezna |
| Olympus America INC. | $42.55 | 2021 | |
| Daiichi Sankyo INC. | $42.26 | 2021 | |
| Ironwood Pharmaceuticals, INC | $42.21 | 2023-2024 | Linzess |
| Shire North American Group INC | $32.89 | 2019 | |
| Evoke Pharma, INC. | $31.45 | 2022-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $23.68 | 2024 | Dificid |
| Janssen Pharmaceuticals, INC | $22.53 | 2022 | |
| Vivus LLC | $21.26 | 2025 | Pancreaze |
| Novo Nordisk INC | $17.23 | 2025 | Wegovy |
| Allergan, INC. | $16.72 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$85,302.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Piesman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.